

**Table S1** Univariate and multivariate analysis of factors associated with SVR12 in the entire cohort

| Variables                        | Univariate          |         | Multivariable      |         |
|----------------------------------|---------------------|---------|--------------------|---------|
|                                  | OR (95% CI)         | P value | aOR (95% CI)       | P value |
| Age, y                           | 0.91 (0.39, 2.10)   | 0.817   |                    |         |
| Male gender                      | 1.88 (0.82, 4.34)   | 0.137   |                    |         |
| Treatment-experienced            | 7.68 (2.91, 20.28)  | <0.001  | 6.09 (1.76, 21.07) | 0.004   |
| Liver stage                      |                     |         |                    |         |
| Non-cirrhosis                    | REF                 |         |                    |         |
| Compensated cirrhosis            | 3.97 (1.63, 9.67)   | 0.002   |                    |         |
| Decompensated cirrhosis          | 12.03 (3.55, 40.71) | <0.001  | 6.59 (1.20, 36.28) | 0.030   |
| History of HCC                   | 4.01 (0.89, 18.02)  | 0.070   |                    |         |
| Genotype                         |                     |         |                    |         |
| 1                                | REF                 |         |                    |         |
| 2                                | 1.62 (0.58, 4.53)   | 0.354   |                    |         |
| 3                                | 4.89 (1.56, 15.31)  | 0.007   |                    |         |
| 6                                | NA                  |         |                    |         |
| Mixed or indeterminate           | NA                  |         |                    |         |
| HCV RNA, Log <sub>10</sub> IU/mL | 0.86 (0.38, 1.96)   | 0.721   |                    |         |
| LSM, kPa                         | 1.03 (0.99, 1.07)   | 0.068   |                    |         |
| ALT, U/L                         | 1.01 (0.99, 1.01)   | 0.819   |                    |         |
| AST, U/L                         | 1.00 (0.99, 1.01)   | 0.391   |                    |         |
| Total bilirubin, µmol/L          | 1.01 (0.99, 1.0)    | 0.178   |                    |         |
| Albumin, g/L                     | 0.96 (0.90, 1.02)   | 0.180   |                    |         |
| AFP, ng/mL                       | 1.00 (1.00, 1.00)   | 0.083   |                    |         |
| Platelets, 10 <sup>9</sup> /L    | 1.00 (0.99, 1.00)   | 0.218   |                    |         |
| Hemoglobin, g/L                  | 1.01 (0.99, 1.03)   | 0.522   |                    |         |
| FIB-4 index                      | 2.16 (0.96, 4.86)   | 0.064   |                    |         |
| Treatment regimen                |                     |         |                    |         |
| SOF + RBV                        | REF                 |         |                    |         |
| EBR/GZR                          | 0.23 (0.05, 1.03)   | 0.054   |                    |         |
| DCV + ASV                        | 0.97 (0.12, 7.76)   | 0.974   |                    |         |
| OBV/PTV/r/DSV ± RBV              | 0.21 (0.08, 0.56)   | 0.002   |                    |         |
| SOF + DCV ± RBV                  | 0.54 (0.12, 2.47)   | 0.430   |                    |         |
| SOF/VEL ± RBV                    | NA                  | 0.984   |                    |         |
| Comorbidity                      |                     |         |                    |         |
| Hypertension                     | 0.42 (0.10, 1.82)   | 0.248   |                    |         |
| Diabetes                         | 1.99 (0.78, 5.10)   | 0.150   |                    |         |
| Cardiovascular disease           | 1.53 (0.20, 11.66)  | 0.685   |                    |         |
| Chronic kidney disease           | 1.64 (0.21, 12.55)  | 0.636   |                    |         |
| HBV coinfection                  | 2.20 (0.28, 17.03)  | 0.451   |                    |         |

SVR12, sustained virologic response at 12 weeks post-treatment; OR, odds ratio; CI, confidence interval; aOR, adjusted odds ratio; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; LSM, liver stiffness measurement; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AFP, alpha-fetoprotein; FIB-4, Fibrosis-4; SOF, sofosbuvir; RBV, ribavirin; EBR, elbasvir; GZR, grazoprevir; DCV, daclatasvir; ASV, asunaprevir; OBV/PTV/r/DSV, ombitasvir/paritaprevir/ritonavir/dasabuvir; VEL, velpatasvir; HBV, hepatitis B virus; REF, reference category; NA, not available.